Abstract:To the Editor: Dermatomyositis (DM) is an autoimmune disease characterized by distinct cutaneous rashes, muscle inflammation, and potential involvement of internal organs. Clinically amyopathic DM (CADM) is a unique subset of DM without myositis. Interstitial lung disease (ILD), especially the fatal type called rapidly progressive ILD (RP-ILD), is a typical complication in patients with DM. Anti-melanoma differentiation-associated gene (MDA)-5 antibodies in patients with DM/CADM are associated with high prevalence of ILD/RP-ILD, poor response to treatment, and a high fatality rate. Moreover, anti–MDA-5 antibodies are also associated with certain cutaneous manifestations, including inverse Gottron papules, mechanic's hands, skin ulceration, and diffuse alopecia.1Fiorentino D. Chung L. Zwerner J. Rosen A. Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.J Am Acad Dermatol. 2011; 65: 34Abstract Full Text Full Text PDF Scopus (369) Google Scholar,2Mariampillai Kuberaka Granger et al.Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies.JAMA Neurol. 2018; 75: 1528-1537Crossref PubMed Scopus (160) Google ScholarWe performed a study of 11 patients, 5 with DM and 6 with CADM.3Bohan A. Peter J.B. Polymyositis and dermatomyositis: part 1 and 2.N Engl J Med. 1975; 292: 344-347Crossref PubMed Scopus (3685) Google Scholar,4Sontheimer R.D. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?.J Am Acad Dermatol. 2002; 46: 626-636Abstract Full Text Full Text PDF PubMed Scopus (347) Google Scholar There were 5 men and 6 women, with a median age of 50.9 years (range, 28-63 years). They were featured by facial seborrheic dermatitis (SD)-distributed rash, manifested as greasy purplish erythema with flaky scales distributed in scalp, forehead, eyebrows, inner canthus, and nasal T zones (Fig 1). ILD was present in 8 of 11 patients.5Morisset J. Johnson C. Rich E. Collard H.R. Lee J.S. Management of myositis-related interstitial lung disease.Chest. 2016; 150: 1118-1128Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar Four patients were diagnosed with RP-ILD,5Morisset J. Johnson C. Rich E. Collard H.R. Lee J.S. Management of myositis-related interstitial lung disease.Chest. 2016; 150: 1118-1128Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar among whom 3 died of respiratory failure and 1 survived, and the average time span from receiving a diagnosis of DM to death was 3.4 months. We also noticed that these 8 patients with ILD had no heliotrope rash, shawl sign, or V sign, but possessed other familiar features: Gottron papules (n = 7), inverse Gottron papules (n = 7), mechanic's hands (n = 3), cutaneous ulceration (n = 3), and diffuse alopecia (n = 2). Anti–MDA-5 antibodies were detected in 6 of the patients with ILD, and all were positive; yet, 3 patients without ILD were negative (Table I).Table IClinical information, skin manifestations, laboratory data, therapies, and clinical course of patientsPatientAge/sexDM/CADMILD/RP-ILDTime span∗Time span: Time from the appearance of the rashes to the diagnosis of ILD.Heliotrope rashGottron papulesInverse Gottron papulesSkin ulcerationMechanic's handsDiffuse alopeciaAnti–MDA-5 antibodiesMedical therapyOutcome157/FCADM+/+5 mo−+++−+Not doneMP, IVIGDied263/MCADM+/+7 d−+−−−−+MP, IVIGDied352/MCADM+/+5 mo−−+−+−Not doneMP, IVIG, CSADied428/FDM+/+14 d−++++++MP, CSA, CTX, IVIG, HCQ, ThalFollow-up559/MCADM+/−2 mo−+++−−+MP, HCQ, CTXFollow-up649/MDM+/−1 mo−++−−−+++MP, HCQFollow-up749/FCADM+/−1 mo−++−−−+++MP, CSAFollow-up834/FCADM+/−4 mo−++−+−+++MPFollow-up952/FDM−/−−−+−−−−−MP, HCQFollow-up1055/FDM−/−−−+−−−−−MP, ThalFollow-up1162/MDM−/−−−+−−−−−MP, HCQFollow-upCADM, Clinically amyopathic dermatomyositis; CSA, cyclosporine A; CTX, cyclophosphamide; DM, dermatomyositis; HCQ, hydroxychloroquine; ILD, interstitial lung disease; IVIG, intravenous immunoglobulin; MDA-5, melanoma differentiation-associated gene 5; MP, methylprednisolone; RP-ILD, rapid progressive interstitial lung disease; Thal, thalidomide.∗ Time span: Time from the appearance of the rashes to the diagnosis of ILD. Open table in a new tab In our study, these patients went to the hospital due to facial dermatitis, and other cutaneous manifestations were found by clinicians. Before being diagnosed with DM, none of them were treated with systemic methylprednisolone or immunosuppressors. Concomitant appearance and similar clinical evolution of the SD-distributed rash with the typical clinical findings of DM, as well as the characteristic erythematous-violaceous background, similar to the heliotrope rash seen in DM, led us to suspect that the SD-distributed rash is a manifestation of DM. ILD/RP-ILD was present in 8 of 11 patients, and the average time from the appearance of the rashes to the diagnosis of ILD was approximately 2.3 months (range, 0.25-5 months). Five patients survived and achieved improvement of both the rashes and ILD after early comprehensive therapies, including methylprednisolone combined with cyclophosphamide, cyclosporine A, and intravenous immunoglobulin. Otherwise, they might develop RP-ILD like the 3 patients who died in our study.Here we describe a type of SD–distributed DM, which is characterized by facial SD-distributed rash. Specifically, patients with SD-distributed DM with positive anti–MDA-5 antibodies are prone to ILD/RP-ILD. Patients with SD-distributed DM with ILD/RP-ILD are often accompanied by Gottron papules and inverse Gottron papules, can be accompanied by mechanic's hands and cutaneous ulceration, and are seldom accompanied by muscle involvement. We therefore suggest that patients with SD-distributed DM undergo anti–MDA-5 antibodies detection and pulmonary examinations. However, further studies should validate this finding as a cutaneous clue of DM by obtaining cutaneous biopsy samples within the SD-distributed areas for histopathologic examination. To the Editor: Dermatomyositis (DM) is an autoimmune disease characterized by distinct cutaneous rashes, muscle inflammation, and potential involvement of internal organs. Clinically amyopathic DM (CADM) is a unique subset of DM without myositis. Interstitial lung disease (ILD), especially the fatal type called rapidly progressive ILD (RP-ILD), is a typical complication in patients with DM. Anti-melanoma differentiation-associated gene (MDA)-5 antibodies in patients with DM/CADM are associated with high prevalence of ILD/RP-ILD, poor response to treatment, and a high fatality rate. Moreover, anti–MDA-5 antibodies are also associated with certain cutaneous manifestations, including inverse Gottron papules, mechanic's hands, skin ulceration, and diffuse alopecia.1Fiorentino D. Chung L. Zwerner J. Rosen A. Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.J Am Acad Dermatol. 2011; 65: 34Abstract Full Text Full Text PDF Scopus (369) Google Scholar,2Mariampillai Kuberaka Granger et al.Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies.JAMA Neurol. 2018; 75: 1528-1537Crossref PubMed Scopus (160) Google Scholar We performed a study of 11 patients, 5 with DM and 6 with CADM.3Bohan A. Peter J.B. Polymyositis and dermatomyositis: part 1 and 2.N Engl J Med. 1975; 292: 344-347Crossref PubMed Scopus (3685) Google Scholar,4Sontheimer R.D. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?.J Am Acad Dermatol. 2002; 46: 626-636Abstract Full Text Full Text PDF PubMed Scopus (347) Google Scholar There were 5 men and 6 women, with a median age of 50.9 years (range, 28-63 years). They were featured by facial seborrheic dermatitis (SD)-distributed rash, manifested as greasy purplish erythema with flaky scales distributed in scalp, forehead, eyebrows, inner canthus, and nasal T zones (Fig 1). ILD was present in 8 of 11 patients.5Morisset J. Johnson C. Rich E. Collard H.R. Lee J.S. Management of myositis-related interstitial lung disease.Chest. 2016; 150: 1118-1128Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar Four patients were diagnosed with RP-ILD,5Morisset J. Johnson C. Rich E. Collard H.R. Lee J.S. Management of myositis-related interstitial lung disease.Chest. 2016; 150: 1118-1128Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar among whom 3 died of respiratory failure and 1 survived, and the average time span from receiving a diagnosis of DM to death was 3.4 months. We also noticed that these 8 patients with ILD had no heliotrope rash, shawl sign, or V sign, but possessed other familiar features: Gottron papules (n = 7), inverse Gottron papules (n = 7), mechanic's hands (n = 3), cutaneous ulceration (n = 3), and diffuse alopecia (n = 2). Anti–MDA-5 antibodies were detected in 6 of the patients with ILD, and all were positive; yet, 3 patients without ILD were negative (Table I). CADM, Clinically amyopathic dermatomyositis; CSA, cyclosporine A; CTX, cyclophosphamide; DM, dermatomyositis; HCQ, hydroxychloroquine; ILD, interstitial lung disease; IVIG, intravenous immunoglobulin; MDA-5, melanoma differentiation-associated gene 5; MP, methylprednisolone; RP-ILD, rapid progressive interstitial lung disease; Thal, thalidomide. In our study, these patients went to the hospital due to facial dermatitis, and other cutaneous manifestations were found by clinicians. Before being diagnosed with DM, none of them were treated with systemic methylprednisolone or immunosuppressors. Concomitant appearance and similar clinical evolution of the SD-distributed rash with the typical clinical findings of DM, as well as the characteristic erythematous-violaceous background, similar to the heliotrope rash seen in DM, led us to suspect that the SD-distributed rash is a manifestation of DM. ILD/RP-ILD was present in 8 of 11 patients, and the average time from the appearance of the rashes to the diagnosis of ILD was approximately 2.3 months (range, 0.25-5 months). Five patients survived and achieved improvement of both the rashes and ILD after early comprehensive therapies, including methylprednisolone combined with cyclophosphamide, cyclosporine A, and intravenous immunoglobulin. Otherwise, they might develop RP-ILD like the 3 patients who died in our study. Here we describe a type of SD–distributed DM, which is characterized by facial SD-distributed rash. Specifically, patients with SD-distributed DM with positive anti–MDA-5 antibodies are prone to ILD/RP-ILD. Patients with SD-distributed DM with ILD/RP-ILD are often accompanied by Gottron papules and inverse Gottron papules, can be accompanied by mechanic's hands and cutaneous ulceration, and are seldom accompanied by muscle involvement. We therefore suggest that patients with SD-distributed DM undergo anti–MDA-5 antibodies detection and pulmonary examinations. However, further studies should validate this finding as a cutaneous clue of DM by obtaining cutaneous biopsy samples within the SD-distributed areas for histopathologic examination. None disclosed.

Melkerson-Rosenthal Syndrome Complicated by Inflammatory Myopathy

Multiple System Atrophy‐like Phenotype Accompanied by Prominent Weight Loss and Fatigue

Retrospective Analysis Of 69 Patients With Melkersson-Rosenthal Syndrome In Mainland China

A Novel Mutation in Mbtps2 Causes Ichthyosis Follicularis, Alopecia and Photophohia Syndrome in A Chinese Family

Multiple painful erythematous nodules on extremities--a clinicopathological challenge.

Edematous Erythema, Subcutaneous Plaques, and Severe Pain in the Lower Extremities in an Immunocompromised Patient.

A case of Melkersson-Rosenthal syndrome with temporomandibular joint osteoarthritis: multidisciplinary treatment and autoimmune etiological hypothesis

Palmoplantar Keratoderma: a New Phenotype in Patients with Hypotrichosis Resulted from Lanosterol Synthase Gene Mutations

Generalized Pure Cutaneous Rosai-Dorfman Disease: a Link Between Inflammation and Cancer Not Associated with Mitochondrial DNA and SLC29A3 Gene Mutation?

Melkersson-Rosenthal Syndrome with Genitalia Involved in a 12-Year-Old Boy.

Complete Melkersson-Rosenthal Syndrome with Multiple Cranial Nerve Palsies.

Compression Therapy: an Adjuvant Treatment for Orofacial Granulomatosis in Melkersson-Rosenthal Syndrome?

An Unusual Case of Multiple Cutaneous Rosai‐Dorfman Disease Involving Two Separate Parts of the Body

Erosive Pustular Dermatosis of the Scalp Associated with Myelodysplastic Syndrome

Clinical Characteristics of 10 Chinese Patients with Melorheostosis and Identification of a Somatic MAP2K1 Variant in One Case.

A Case of Complete Melkersson-Rosenthal Syndrome: Possibly Associated with Mycolicibacterium Fortuitum from Odontogenic Origin.

Mucocutaneous Manifestations of Inflammatory Bowel Disease in Central China -a Single-Centre Study.

A Case of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type with Dermatomyositis

Seborrheic Dermatitis-Distributed Rash in Dermatomyositis is Associated with Progressive Interstitial Lung Disease

Decreased Muscle Strength, Type 2 Respiratory Failure, Heart Failure, Positive Anti-mitochondrial Antibodies—Rare Atypical Manifestations of Inflammatory Myopathy

Incompletely penetrant <i>TRPM4</i>-associated progressive symmetric erythrokeratodermia responses to methotrexate